"The US price of Humira, which AbbVie has increased more than 20 times to exploit its monopoly there, is finally under pressure. Having been legally shielded until now, the drug this year faces competition from nine “biosimilars” such as Amgen’s Amjevita. This may bring relief to patients who have faced bills of thousands of dollars, despite being insured."

https://www.ft.com/content/a8685c8d-60da-4fe8-9bba-ec1ba3bf62cc